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a b s t r a c t
Salmonella spp. are Gram-negative, facultative, intracellular pathogens that cause several diarrheal dis-
eases ranging from self-limiting gastroenteritis to typhoid fever. Previous results from our laboratory
showed that Saccharomyces cerevisiae strain UFMG 905 isolated from ‘cachac¸a’ production presented
probiotic properties due to its ability to protect against experimental infection with Salmonella enterica
serovar Typhimurium. In this study, the effects of oral treatment with S. cerevisiae 905 were evaluated at
the immunological level in a murine model of typhoid fever. Treatment with S. cerevisiae 905 inhibited
weight loss and increased survival rate after Salmonella challenge. Immunological data demonstrated thatalmonella enterica serovar Typhimurium
ytokines
AP kinases
F-B
P-1
S. cerevisiae 905 decreased levels of proinﬂammatory cytokines andmodulated the activation ofmitogen-
activated protein kinases (p38 and JNK, but not ERK1/2), NF-B and AP-1, signaling pathways which are
involved in the transcriptional activation of proinﬂammatory mediators. Experiments in germ-free mice
revealed that probiotic effects were due, at least in part, to the binding of Salmonella to the yeast. In
conclusion, S. cerevisiae 905 acts as a potential new biotherapy against S. Typhimurium infection due to
its ability to bind bacteria and modulate signaling pathways involved in the activation of inﬂammation
hoid fin a murine model of typ
ntroduction
In recent years,worldwide interest in the use of functional foods
ontaining probiotic bacteria for health promotion and disease
revention has increased signiﬁcantly. According to the currently
dopted deﬁnition by the World Health Organization, probiotics
re ‘live microorganisms which when administered in adequate
mounts confer a health beneﬁt to the host’ (FAO/WHO, 2002). Pre-
ious results obtained in our laboratory showed that Saccharomyces
erevisiae strain UFMG 905, isolated from ‘cachac¸a’ (a Brazilian
ypical beverage) production, was able to colonize and survive in
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iológicas, Universidade Federal de Minas Gerais, Av. Antonio Carlos, 6627, C.P. 486,
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the gastrointestinal tract of germ-free and conventional mice and
to protect them against experimental infections with Salmonella
enterica serovar Typhimurium and Clostridium difﬁcile (Martins
et al., 2005). Our results also showed that protectionwas not due to
a reduction of the intestinal population of the pathogenic bacteria.
Additional results showed that S. cerevisiae 905 was able to reduce
the translocation of S. Typhimurium and to stimulate the immune
system in mice (Martins et al., 2007). At the histological level, S.
cerevisiae 905 conferred protection to intestine and liver tissues,
decreased inﬂammatory foci in liver, and promoted an increase in
the number of Kupffer cells after experimental infection with S.
Typhimurium (Martins et al., 2005). Recent data demonstrated that
this yeast protected against bacterial translocation, preserved gut
Open access under the Elsevier OA license.barrier integrity, and stimulated the immune system in a murine
model of intestinal obstruction (Generoso et al., 2010).
With an estimated 16–33 million annual cases which result in
500,000–600,000 deaths in endemic areas, the World Health Orga-
nization identiﬁes typhoid fever as a serious public health problem
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Crumpet al., 2004). Salmonella spp. areGram-negative, facultative,
ntracellular pathogens that cause several diarrheal diseases rang-
ng from self-limiting gastroenteritis to typhoid fever. In humans,
yphoid fever is caused by Salmonella enterica serovar Typhi. An
ssential feature of the pathogenicity of Salmonella is their ability to
ngage the host cell in a two-way biochemical interaction, or cross-
alk, which leads to responses from both the bacteria and the host
ell (Galán and Bliska, 1996). The bacterium induces its ownuptake
hrough virulent proteins delivered into cytoplasm of infected cells
y a specialized mechanism known as type III protein secretion
ystem (TTSS) (Collazo and Galán, 1996; Zaharik et al., 2002) that
ctivates signaling pathways involved in cytoskeleton rearrange-
ents and cellular uptake processes (Galán and Collmer, 1999).
his interaction between invading pathogen and host epithelium
lso leads to activation of a program of epithelial gene expres-
ion, such as those with proinﬂammatory functions (Kagnoff and
ckmann, 1997). Consequently, initial invasion results in the acti-
ationof various transcription factorswhichultimately result in the
roduction of proinﬂammatory cytokines such as IL-8, in response
o Salmonella-mediated activation of mitogen-activated protein
inase (MAPK) cascade and activation of transcription factors such
s AP-1 (activator protein 1) and NF-B (nuclear factor kappa B)
Hobbie et al., 1997). This is an important event in Salmonella
athogenesis, since one of the hallmarks of salmonellosis is the
timulation of a profuse inﬂammatory diarrhea induced by pro-
nd inﬂammatory cytokines.
Here, we evaluated the effects of oral treatment with S. cere-
isiae 905 on Salmonella-induced infection in mice. We show that
robiotic treatment reduced weight loss and mortality and modu-
ated signalingpathways involved in theactivationof inﬂammatory
esponses induced by Salmonella.
aterials and methods
icroorganisms and growth conditions
The bacterial strain Salmonella enterica serovar Typhimurium
ATCC 14028) was kindly provided by Oswaldo Cruz Foundation
FIOCRUZ), Rio de Janeiro, RJ, Brazil. The bacterium was stored at
80 ◦C in Brain Heart Infusion (BHI) medium (Difco, Sparks, MD,
SA) with 15% glycerol and grown in BHI broth at 37 ◦C during 18h
nder aerobic conditions without shaking for reactivation.
S. cerevisiae strain UFMG 905 belongs to the Yeasts Bank of Dr.
arlos A. Rosa (Laboratory of Ecology and Biotechnology of Yeasts,
ept. ofMicrobiology, Federal University ofMinasGerais, BeloHor-
zonte, MG, Brazil). Identity of the strain was determined as S.
erevisiae using the computer program YEASTCOMPARE (Ciriello
nd Lachance, 2001). The yeast was grown overnight at 37 ◦C,
ith shaking, in YPD (yeast extract 1%, peptone 1%, and dextrose
%) broth. The culture was then concentrated to obtain 9.0 log of
olony-forming units (CFU) ml–1.
ice, treatment, and infection procedures
Germ-free 21–23-day-old NIH mice (Taconic, Germantown,
Y, USA) were used in this work. The animals were housed in
exible plastic isolators (Standard Safety Equipment Company,
cHenry, IL, USA) andhandled according to establishedprocedures
Pleasants, 1974). Experiments with gnotobiotic mice were car-
ied out in microisolators (UNO Roestvaststaal B.V., Zevenaar, The
etherlands). Conventional NIH mice were derived from the germ-
ree colony and only used after at least 2 generations following
he conventionalization. Water and commercial autoclavable diet
Nuvital, Curitiba, PR, Brazil) were sterilized by steam and admin-
stered ad libitum, and animals were maintained in an open animaldical Microbiology 301 (2011) 359–364
house with controlled lighting (12h light, 12h dark). All experi-
mental procedures were carried out according to the standards
set forth in the ‘Guide for the Care and Use of Laboratory Ani-
mals’ (National Research Council, 1996). The study was approved
by the Ethics Committee in Animal Experimentation of the Federal
University of Minas Gerais (CETEA/UFMG, protocol no. 197/2007).
For probiotic treatment, conventional experimental mice
received by oral gavage a daily dose of 0.1ml containing
9.0 logCFUml–1 10 days before infection, and treatment was con-
tinued during all the experimental infection. Germ-free mice
received by oral gavage a unique dose of 0.1ml containing
9.0 logCFUml–1 10 days before infection. Control mice received
only sterilewater by oral gavage following the sameprocedure that
their experimental counterparts. For S. Typhimuriumexperimental
infection, conventional mice were inoculated intragastrically with
0.1ml of a bacterial suspension containing 5.0 logCFUml–1.
Experimental design
To evaluate the effects of the treatment with the yeast on the
morbidity and mortality during an experimental bacterial chal-
lenge, 30 conventional animals were divided into 3 groups (n=10
in each group): (C) control 1 group (mice receiving only ster-
ile water by oral gavage), (ST) mice receiving sterile water by
oral gavage and challenged with S. Typhimurium, and (905+ST)
mice treated by oral gavage with S. cerevisiae 905 and challenged
with S. Typhimurium. During 38 days (10 days of yeast pretreat-
ment before challenge and 28 days post-challenge) mice were
analyzed for clinical signs, weight, and mortality induced by S.
Typhimurium infection. Clinical signs were evaluated by diarrhea
(consistency and presence of feces on cages wall), morbidity, and
fecal blood (Hemaccult cards, INLAB-Diagnostica, São Paulo, SP,
Brazil).
For molecular and immunological analysis, 60 conventional
animals were divided into 2 groups (n=30 in each group): (ST)
control mice receiving sterile water and then challenged with S.
Typhimurium, and (905+ST) experimental mice receiving S. cere-
visiae 905 and then challenged with S. Typhimurium. By days 0, 1,
5, 10, and 15 post-challenge, 5 animals of each group were sacri-
ﬁced by cervical dislocation. Colons were collected for ELISA and
Western blot.
For experiments of probiotic–pathogen binding, germ-freemice
were used. Mice were pretreated with S. cerevisiae 905 during 10
days and then inoculated intragastrically with 0.1ml of a bacterial
suspension containing 7.0 logCFUml–1. After 2h, mice were sacri-
ﬁced by cervical dislocation, and the small intestine tissues were
ﬁxed and processed for scanning electron microscopy.
Cytokines and chemokine determinations
The concentration of CXCL-1/KC, IL-6, IL-10, TGF-, TNF-, and
IFN-were measured by ELISA in colons of animals using commer-
cially available antibodies according to the procedures supplied by
the manufacturer (R&D Systems, Minneapolis, MN, USA). Aliquots
of the colon (100mg) were homogenized in 1ml PBS (0.4M
NaCl and 10mM NaPO4) containing antiproteases (0.1mM PMSF,
0.1mM benzethonium chloride, 10mM EDTA, and 20 KI aprotinin
A) and 0.05% Tween 20. The samples were then centrifuged for
10min at 10,000 rpm, and the supernatantwas collected, diluted at
1:3 inPBS, andused immediately for assays, aspreviouslydescribed
(Souza et al., 2004).Cytosolic and nuclear extracts and Western blotting analysis
Nuclear extracts were obtained from powdered colon and
prepared as describedbyDignamet al. (1983)withminormodiﬁca-
of Medical Microbiology 301 (2011) 359–364 361
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Fig. 1. Effect of treatmentwith S. cerevisiae905onweight gain (A) and survival (B) of
mice non-treated and non-challenged (Control), mice receiving orally sterile waterF.S. Martins et al. / International Journal
ions (Souza et al., 2009). Brieﬂy, 30mgof tissuewerehomogenized
n ice-cold hypotonic lysis buffer (10mM Tris pH 7.4, 10mM NaCl,
mMMgCl2, 0.002%NaN3, 1mMPMSF, 0.1mMEGTA, 10Mapro-
inin, 20M leupeptina, 0.5mM DTT, 25mM NaF) chilled on ice for
5min and then 5%NP-40 added for further 5min. The supernatant
ontaining the cytosolic fractionwas removed and stored at−80 ◦C.
he nuclear pellet was ressuspended in 200l of high salt extrac-
ion buffer (20mM HEPES pH 7.4, 420mM NaCl, 1.5mM MgCl2,
.01% NaN3, 0.2mM EDTA, 25% (v/v) glycerol, 1mM PMSF, 10M
protinin, 20M leupeptin, 0.5mM DTT) and incubated with shak-
ng at 4 ◦C for 30min. The nuclear extract was then centrifuged for
5min at 13,000 rpm, and supernatant was aliquoted and stored at
80 ◦C. Whole-cell extracts were prepared as previously described
Sousa et al., 2005). Proteinwas quantiﬁed using the Bradford assay
eagent from Bio-Rad (Hercules, CA, USA).
Nuclear (30g) or whole- (60g) cell extracts were separated
yelectrophoresis onadenaturing10%polyacrylamide-SDSgel and
ransferred to nitrocellulose membranes, as previously described
Sousa et al., 2005). Membranes were blocked overnight at 4 ◦C
ith PBS containing 5% (w/v) non-fat dry milk and 0.1% Tween
0, washed 3 times with PBS containing 0.1% Tween 20, and
hen incubated at a dilution of 1:1000 with speciﬁc primary anti-
odies: anti-p65/RelA (Santa Cruz Biotechnology, Santa Cruz, CA,
SA), anti-phospho-p38, anti-phospho-ERK1/2, anti-phospho-JNK,
nti-phospho-IB-, anti-phospho-jun, anti-fos (Cell Signaling
echnology, Beverly, MA, USA), or -actin (Sigma-Chemicals, St.
ouis, MO, USA) in phosphate-buffered saline containing 5% (w/v)
SA and 0.1% Tween 20. After washing, membranes were incu-
atedwithhorseradish peroxidase-conjugated secondary antibody
1:3000, Cell Signaling Technology). Immunoreactive bands were
isualizedbyusing an enhanced chemiluminescencedetection sys-
em, as described by the manufacturer (GE Healthcare, Piscataway,
J, USA).
canning electron microscopy (SEM)
Tissues (cecum)were ﬁxed overnight at room temperaturewith
.5% glutaraldehyde in 0.1M cacodylate buffer pH 7.2. Then, they
ere treated with 1% osmium tetroxide solution plus 0.2% potas-
ium ferrocyanide in the samebuffer for 1h. After dehydrationwith
ncreasingacetone concentrations (30–100%), tissuesweredriedby
he critical point devicewith CO2, as previously described (Pimenta
nd De Souza, 1985). The next steps were mounting in SEM stubs,
oating with gold particles in a sputtering, and analyzing in a JEOL
600 SEM.
tatistical analysis
The results were expressed as the average of at least 2 indepen-
ent experiments. The data were statistically analyzed using the
xact Fisher or Student’s t-test at a probability level of 0.05. Statis-
ical analyseswereperformedusing theprogramSigmaStat (Jandel
cientiﬁc Software, version 1.0, San Rafael, CA, USA).
esults
. cerevisiae 905 inhibited weight loss and increased survival of
ice after S. Typhimurium infection
Mice only infected with S. Typhimurium (ST) stopped gaining
ody weight just after infection and failed to recover until 20 days
hen compared to the uninfected (C) group (Fig. 1A). In addition,
almonella infectioncaused thedeathof60%ofmicebyday28of the
xperiment (Fig. 1B). Mice with an administration of S. cerevisiae
05 (905) 10 days before S. Typhimurium infection maintained
similar body weight gain after the pathogenic challenge whenand challengedwith S. Typhimurium (ST), ormice pretreated orallywith S. cerevisiae
905 and challenged with S. Typhimurium (905). n=10 in each group. *P<0.05 in
relation to control group. Arrows indicates the day of Salmonella infection.
compared to the uninfected group (Fig. 1A) and induced a lower
mortality rate (20%) than in ST group (P<0.05). Diarrhea and fecal
blood were mainly observed in animals in the ST group (data not
shown).
S. cerevisiae 905 diminished inﬂammatory cytokines induced in
mice challenged with S. Typhimurium
The interaction between S. Typhimurium and host epithelium
leads to activation of a program of epithelial gene expression, such
as those with proinﬂammatory functions, including chemokines
and cytokines with inﬂammatory properties. To assess the effects
of S. cerevisiae905 on cytokine production in the colon ofmice chal-
lenged with S. Typhimurium, animals were divided into 2 groups,
as described above, and the chemokine CXCL-1/KC (the mouse
ortholog of GRO-) and cytokines IL-6, TNF-, IFN-, IL-10, and
TGF- were measured at 0, 1, 5, 10, and 15 days post-infection.
As shown in Fig. 2, S. cerevisiae 905 diminished basal levels of all
cytokines measured at the day of the infection with Salmonella (i.e.,
10 days after the beginning of treatment with S. cerevisiae 905).
Basal levelsof TNF- (Fig. 2C) andTGF- (Fig. 2E)wereundetectable
in treated animals. S. Typhimurium infection induced an increase in
several cytokines, particularly for higher levels of KC, IL-6, TNF-,
and INF- in ST mice by day 10 after infection (Fig. 2). In animals
which were given S. cerevisiae 905 prior to infection, levels of KC
were similar to those found in uninfectedmice during all the exper-
imental period (Fig. 2A), and a statistically signiﬁcant decrease was
observed for levels of IL-6 (Fig. 2B) and TNF- (Fig. 2C) by day 10
post-challenge with Salmonella.
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Wig. 2. Effects of S. cerevisiae 905 on KC (A), IL-6 (B), TNF- (C), IFN- (D), IL-10
yphimurium (ST) and mice pretreated orally with S. cerevisiae 905 and challenged
ays after infection. n=5 for each point. *P<0.05 in relation to Salmonella-infected
. cerevisiae 905 controls inﬂammation through inhibition of
ignal pathways involved in inﬂammatory responseOnce S. cerevisiae 905 decrease the levels of inﬂammatory
ytokines induced by Salmonella infection in mice (Fig. 2), a pos-
ible modulation by the yeast of signaling transduction pathways
hat govern the induction of such cytokines during the course of
almonella infection in mice was investigated. Thus, MAPKs (p38,
ig. 3. Effects of S. cerevisiae 905 on S. Typhimurium-induced p38, JNK, and ERK1/2 MAPK
nd c-fos) activation (C) in the colon of mice receiving orally sterile water and challeng
hallenged with S. Typhimurium (905+ST). Samples were fractioned in SDS-PAGE and an
estern blots showed are one representative of 3 similarly, but independently performend TGF- (F) levels in mice receiving orally sterile water and challenged with S.
. Typhimurium (905+ST). Cytokines contents were estimated by ELISA in different
for the same day.
JNK, and ERK1/2) (Fig. 3A), NF-B (p65-RelA and phospho-IB-)
(Fig. 3B), and AP-1 (phospho-jun and c-fos) (Fig. 3C) were analyzed
at 0, 1, 5, 10, and 15 days post-infection. As it can be observed,
Salmonella activated p38 and JNK MAPKs (Fig. 3A), as soon as pro-
moted p65/RelA nuclear translocation and phosphorylation of its
inhibitory protein (IB-) (Fig. 3B), and activated AP-1 (indirectly
analyzed by phospho-jun and c-fos activation) (Fig. 3C). In the pres-
ence of the yeast, activation of JNK was completely abolished, p38
s activation (A), NF-B (p65/RelA and P-IB) activation (B), and AP-1 (phospho-jun
ed with S. Typhimurium (ST) or mice pretreated orally with S. cerevisiae 905 and
alyzed by immunoblotting with speciﬁc antibodies in total or nuclear extracts. The
d.
F.S. Martins et al. / International Journal of Me
Fig. 4. Scanning electron microscopy showing S. Typhimurium adhesion on S. cere-
visiae 905 cells in cecum tissue. (A) S. Typhimurium-infected mice, (B–F) mice
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microscopy showed that bacterial cells bound preferentially to S.reviously treated with S. cerevisiae 905 and then infected with S. Typhimurium.
mall arrows indicate S. Typhimurium, thick arrows indicate yeast cells. Magniﬁca-
ion is shown in each ﬁgure.
as diminished, and ERK1/2 was not affected (Fig. 3A). The yeast
ompletely inhibited the translocation of NF-B p65 to the nucleus
nd also diminished the phosphorylation of IB-, a hallmark of
B degradation (Fig. 3B), and signiﬁcantly diminished activation
f AP-1 (through phospho-jun and c-fos analysis) as well (Fig. 3C).
. cerevisiae 905 affects S. Typhimurium translocation via
acteria–yeast binding
Since we have observed that the yeast was able to retard
almonella translocation in a germ-free mouse model and pre-
ented translocation in conventional mice (Martins et al., 2007)
nd that this effect was not due to lowering in bacterial coloniza-
ion (Martins et al., 2005),wehave hypothesized that the yeastmay
e protectingmice and preventing translocation via binding to bac-
eria, as we have previously observed in a cell culture model for
accharomyces boulardii (Martins et al., 2010). To test our hypoth-
sis, an in vivo model using germ-free mice was used to visualize
he interaction between the yeast and the pathogenic bacterium
ithout the interference of the indigenous microbiota. As it can be
een in Fig. 4, in Salmonella mono-infected mice, bacteria covered
he epithelium in a homogeneously distributed way (Fig. 4A), but
hen mice were mono-associated with the yeast prior to adding
acteria, binding between yeast and bacteria was clearly observed
Fig. 4B–F). Additionally, in the presence of Saccharomyces, the bac-
eria seemed to be attracted to the yeast surface and were not
omogeneously distributed.dical Microbiology 301 (2011) 359–364 363
Discussion
We have previously demonstrated that S. cerevisiae 905 had
a potential for probiotic use because of its ability to survive in
the mammal gastrointestinal tract and to protect mice against
S. Typhimurium and C. difﬁcile infections in mice (Martins et al.,
2005) as well as to inhibit bacterial translocation and to modulate
both local and systemic immunity (Martins et al., 2007; Generoso
et al., 2010). The present study conﬁrms this potential and presents
some of the mechanisms which can explain the protective effect
of the yeast in a murine model experimentally infected with S.
Typhimurium. Infectionofmicewith Salmonella inducedsigniﬁcant
clinical manifestations, tissue damage, and lethality, which were
associated with an activation of inﬂammation-signaling pathways.
Previous treatment with S. cerevisiae 905 prevented this activation
of signaling pathways with consequent reduction of inﬂammation,
clinical manifestations, tissue damage, and death. Mechanistically,
this preventing effect could be due, at least in part, to a preferential
binding of the Salmonella to the yeast than to gut epithelial cells.
In the majority of cases, infectious diarrhea is treated through
rehydration or an eventual use of antibiotics. However, the World
Health Organization has recommended the search for alternative
treatments for infection, andprobiotics have beenproposed for this
purpose (Vieira et al., 2008). Although no proof of efﬁcacy of such
treatmentagainst salmonellosishasbeendemonstrated inhumans,
results obtained in murine models have indicated that some probi-
otic microorganisms may be efﬁcient against Salmonella infection
(Jain et al., 2008, 2009; Truusalu et al., 2008; Martins et al., 2009).
In mice, infection with S. Typhimurium gives rise to enteric
fever, with symptoms similar to those observed in humans after
infection with S. Typhi (Eisenstein, 1999; Santos et al., 2001), such
as intense inﬂammation characterized by the release of proinﬂam-
matory cytokines (IL-1 and TNF-) and chemokines (KC). Other
proinﬂammatory cytokines involved in host defense against S.
Typhimurium infection include IFN-, IL-12, and IL-18. In the anti-
inﬂammatory group of cytokines, IL-4, IL-10, and TGF- have been
shown to down-regulate inﬂammatory responses (reviewed by
Eckmann and Kagnoff, 2001; Coburn et al., 2007). The release
of inﬂammatory cytokines is under the control of many signal
transduction pathways, including NF-B and AP-1 transcription
factors, and MAPK pathway (Hobbie et al., 1997; Hoffmann et al.,
2002). In the present study, the inhibitory effect of the yeast on
the inﬂammatory response induced by Salmonella infection was
demonstrated, and this seems to be a major mechanism by which
the yeast prevented inﬂammation and disease after Salmonella
infection. To explain why the treatment with the yeast, before
Salmonella challenge, diminished all the cytokines evaluated, it
could be speculated that the yeast could: (i) down-regulate the
baseline inﬂammation and/or the complex balance between Th1
and Th2 responses, as already observed by Jawhara and Poulain
(2007), (ii) modulate the population levels of some members of the
intestinal microbiota, which in turn could, in part, down-regulate
the immune system, as reviewed by Wohlgemuth et al. (2010)
and Reiff and Kelly (2010), and (iii) up-regulate anti-inﬂammatory
cytokines at the beginning of infection.
In an attempt to deﬁne the mechanisms by which S. cerevisiae
905 prevented the activation of inﬂammation-signaling pathways
normally induced by the Salmonella infection, a possible binding
between the yeast and the bacteria was evaluated. Experiments
were conducted in germ-free mice to facilitate the visualization
of the interaction between the yeast and bacteria. The electroniccerevisiae 905 than to intestinal epithelial cells when the yeast was
present. Some authors have already demonstrated that bacteria
expressing type 1 ﬁmbria, such as Salmonella and Escherichia coli,
are able to bind to S. boulardii and some strains of S. cerevisiae
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hrough mannose residues (Kornonen et al., 1981; Gedek, 1999;
erez-Sotelo et al., 2005; Martins et al., 2010). It is very reasonable
o hypothesize that the binding of S. Typhimurium to S. cerevisiae
05 surface instead of to mice epithelium surface could be respon-
ible for the diminution of activation of MAPKs, NF-B, AP-1, and
onsequently of inﬂammatory cytokine production.
In conclusion, S. cerevisiae 905 acts as a potential new biother-
py against S. Typhimurium infection in part due to its interference
n signal pathways involved in the activation of inﬂammation in
typhoid fever murine model. Electronic microscopy data sug-
est that preferential binding of the bacteria to the yeast prevents
ctivation of proinﬂammatory signal transduction pathways in
pithelial cells with consequent diminishing of inﬂammation.
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